focus -WSS

focus

author：explore 2025-08-28 08:47:02 - browse：28

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the fourth quarter:

The Food and Drug Administration’s decision in June to grant conditional approval to a gene therapy for Duchenne muscular dystrophy was a watershed moment for the treatment of the neuromuscular disease, and a big win for its maker, Sarepta Therapeutics. Confirming the gene therapy’s benefit — and potentially broadening its use to include older boys — will be determined by a Phase 3 clinical trial that will read out later this quarter.

Pfizeris developing its own gene therapy for Duchenne in a fully enrolled Phase 3 study with final results expected in 2024. But before the verdict is revealed, Pfizer intends to conduct an interim analysis later this quarter. The most likely outcome of this early look will be a determination to continue the study to its completion. But surprises — including an early stop for overwhelming efficacy — can’t be ruled out.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Global cancer cases to surge 77% by 2050, WHO report says

WSS

Long Covid needs a new name — and a new frame

Global cancer cases to surge 77% by 2050, WHO report says

New weight loss drugs vying to be the next Wegovy or Mounjaro

Updated Covid vaccine has 54% effectiveness, new study suggests

How housing is health care on Long Island

PEPFAR is under serious threat — and so is global health

focus

focus

focus

23andMe had bad news about my health. I wish a person had delivered it

What to make of Biden’s latest efforts on cancer research

Malaria cases in Florida and Texas: Here’s what you need to know

How housing is health care on Long Island

Activists slam private health insurers over coverage restrictions

FDA proposes changes to key medical devices approval pathway

Virginia high school admissions case could be legal follow

Padmanee Sharma of MD Anderson at center of lawsuit over credit

23andMe had bad news about my health. I wish a person had delivered it

New Covid vaccine is recommended for everyone 6 months or older

hotspot

FDA panel endorses Alnylam’s heart drug — after picking it apart

Why CTE doesn’t keep Americans from enjoying the Super Bowl

Adopting new red light myopia treatments may be short

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

Bernie brings in new pharma CEOs to talk drug prices

Global cancer cases to surge 77% by 2050, WHO report says

explore

leisure time

focus

hotspot